ReviewClinical microbiology reviews2003
Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans.
Review in Clinical microbiology reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 3 syntheses or guidelines pooled it, 325 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Association between the IL-10 and IL-6 polymorphisms and brucellosis susceptibility: a meta-analysis.BMC medical genetics · 2020Pooled it
- Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.Journal of immunology research · 2018Pooled it
- Disruption of Histidine Biosynthesis Impairs Outer Membrane Stability and Intracellular Survival ofMicroorganisms · 2026Article
- Modern Strategies for Brucellosis Vaccination: From Traditional Approaches to Innovative Platforms.Vaccines · 2026Review
- Neurobrucellosis in an 11-year-old child: A rare case report of brain microabscesses from an endemic region.The Journal of international medical research · 2026Article
- Seropositivity and diagnostic challenges of bovine brucellosis in Limpopo and Free State (2013-2022).The Onderstepoort journal of veterinary research · 2025Article
- Reverse vaccinology-driven construction and bioinformatics validation of a multi-epitope vaccine against Brucella spp.Scientific reports · 2025Article
- FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection AgainstVaccines · 2025Article
- Comparison of Long-Term Antibody Titers in Calves Treated with Different Conjunctival and SubcutaneousAnimals : an open access journal from MDPI · 2025Article
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
- Pediatric neurobrucellosis and atypical Guillain-Barré syndrome: an intriguing case unveiled.Journal of medicine and life · 2024Article
- Motor polyradiculoneuropathy as an unusual presentation of neurobrucellosis: a case report and literature review.BMC infectious diseases · 2024Review
- Brucellosis: Unveiling the complexities of a pervasive zoonotic disease and its global impacts.Open veterinary journal · 2024Review
- New insights into the genetic predisposition of brucellosis and its effect on the gut and vaginal microbiota in goats.Scientific reports · 2023Article
- Protective Effects againstJournal of microbiology and biotechnology · 2023Article
- Review
- Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice.Vaccines · 2023Article
- Immuno-profiling ofFrontiers in microbiology · 2023Article
- Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to theExperimental and therapeutic medicine · 2023Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Brucellosis caused by Brucella spp. is a major zoonotic disease. Control of brucellosis in agricultural animals is a prerequisite for the prevention of this disease in human beings. Recently, Brucella melitensis was declared by the Centers for Disease Control and Prevention to be one of three major bioterrorist agents due to the expense required for the treatment of human brucellosis patients. Also, the economic agricultural loss due to bovine brucellosis emphasizes the financial impact of brucellosis in society. Thus, vaccination might efficiently solve this disease. Currently, B. abortus RB51 and B. melitensis REV.1 are used to immunize cattle and to immunize goats and sheep, respectively, in many countries. However, these genetically undefined strains still induce abortion and persistent infection, raising questions of safety and efficiency. In fact, the REV.1 vaccine is quite virulent and apparently unstable, creating the need for improved vaccines for B. melitensis. In addition, Brucella spp. may or may not provide cross-protection against infection by heterologous Brucella species, hampering the acceleration of vaccine development. This review provides our current understanding of Brucella pathogenesis and host immunity for the development of genetically defined efficient vaccine strains. Additionally, conditions required for an effective Brucella vaccine strain as well as the future research direction needed to investigate Brucella pathogenesis and host immunity are postulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.